Acuson turns in strong financials
Ultrasound vendor Acuson of Mountain View, CA, released year-end financial results this month that showed double-digit growth in revenues and net income. The company credited the performance to momentum generated by its Sequoia and Aspen products, as
Ultrasound vendor Acuson of Mountain View, CA, released year-end financial results this month that showed double-digit growth in revenues and net income. The company credited the performance to momentum generated by its Sequoia and Aspen products, as well as a robust U.S. market.
For the year (end-December), Acuson had revenues of $437.8 million, up 26% compared with $346.2 million in 1996. The vendor's net income for the year was $22.4 million, compared with a net loss of $10.6 million in 1996, when costs associated with the Sequoia and Aspen launches sent the company into the red.
For the fourth quarter, Acuson's sales were $117.4 million, up 25% over the same period the year before, when the company recorded $93.7 million in revenues. Net income for the most recent period was $6.3 million, compared with a net loss of $2.9 million in the fourth quarter of 1996.
Acuson achieved the revenue growth despite weakness in the Asian and European markets, according to chairman and CEO Samuel Maslak. Market conditions remain positive in 1998, with the U.S. market showing continued strength and the European market stabilizing. Asia will continue to experience difficulties in 1998, but the company remains committed to expansion in the region, Maslak said.
Can CT-Based Deep Learning Bolster Prognostic Assessments of Ground-Glass Nodules?
June 19th 2025Emerging research shows that a multiple time-series deep learning model assessment of CT images provides 20 percent higher sensitivity than a delta radiomic model and 56 percent higher sensitivity than a clinical model for prognostic evaluation of ground-glass nodules.
FDA Clears Ultrasound AI Detection for Pleural Effusion and Consolidation
June 18th 2025The 14th FDA-cleared AI software embedded in the Exo Iris ultrasound device reportedly enables automated detection of key pulmonary findings that may facilitate detection of pneumonia and tuberculosis in seconds.
